CEO Executive AssistantTime management for pharma medical affairs is one of the most nuanced executive challenges in the pharmaceutical industry. Medical affairs sits at the intersection of science, clinical practice, and commercial strategy, and the CEO’s relationship with that function shapes how effectively the company translates scientific knowledge into market impact. Get the balance wrong in one direction and you signal to the field that medical affairs is an afterthought. Get it wrong in the other direction and you find yourself in the operational details of publication planning and congress strategy when your time belongs at the enterprise level.
The pharmaceutical CEOs who navigate this best treat medical affairs as a strategic asset, not an administrative function, and they structure their time with that distinction in mind.
Why Time Management for Pharma Medical Affairs Requires a Distinct Approach
Medical affairs is structurally different from most other functions a pharma CEO oversees. It operates under regulatory constraints that limit how scientific exchange can occur. It generates influence through relationships rather than transactions, particularly through engagement with key opinion leaders whose adoption behaviors shape prescribing patterns across the field. And it sits in a permanent tension between scientific independence and commercial alignment that requires active executive management.
A McKinsey analysis of pharmaceutical company performance found that companies where medical affairs functions are tightly integrated with commercial strategy consistently outperform those where the two operate as parallel but disconnected tracks. That integration does not happen automatically; it requires the CEO to actively bridge the two functions, and that requires deliberate time allocation.
The failure modes are predictable. CEOs who give medical affairs unlimited access to their time end up spending hours in publication committee reviews, MSL training discussions, and KOL relationship updates that could be handled one level down. CEOs who give medical affairs too little time end up with a function that is either captured by commercial priorities and loses its scientific credibility, or that operates as a scientific island disconnected from the company’s strategic agenda.
The Medical Affairs Functions That Require CEO Attention
Before designing a time allocation model, it helps to be precise about which medical affairs activities genuinely require CEO involvement and which do not.
CEO attention is warranted for: KOL engagement strategy at the most senior levels, particularly for therapeutic areas that are central to the pipeline; major publication strategy decisions, especially for pivotal trials and data sets that will define the company’s scientific positioning; medical affairs budget and resource allocation decisions; the relationship between medical affairs leadership and commercial leadership when tensions arise; and external scientific advisory board engagements where the CEO’s presence signals organizational commitment.
CEO attention is not warranted for: individual MSL deployment decisions; publication timelines for secondary endpoints; congress logistics; individual KOL relationship management below the tier-one level; and internal medical affairs training programs.
The boundary matters because medical affairs teams, like most functions, will expand to fill the executive attention available to them. A CEO who shows interest in congress strategy will be invited to congress planning meetings. A CEO who asks about individual KOL relationships will receive updates on individual KOL relationships. Calibrate your interest and your access to the level where your involvement creates strategic value.
Structuring Your Time Around KOL Engagement Strategy
KOL engagement is where the CEO’s personal time investment in medical affairs generates the most leverage. Senior KOLs, particularly those who shape therapeutic area guidelines, train residents, and speak at major conferences, form opinions about pharmaceutical companies based in part on their perception of leadership quality. A CEO who has a substantive scientific conversation with a leading investigator creates a relationship that no MSL interaction can replicate.
The discipline is in being selective. You cannot personally engage with every KOL in every therapeutic area. You should engage with the small number whose influence is most consequential: the investigators leading major trials in your pipeline areas, the society leaders who shape treatment guidelines, the academic department heads whose fellows will become the next generation of prescribers.
Identify five to ten individuals per year where CEO-level engagement adds strategic value. Build those engagements into your calendar as protected commitments: attendance at the specific congress where they are presenting, a dinner or breakfast meeting at a scientific forum, participation in your company’s advisory board meeting where they are present. These are not casual conversations; they are strategic relationship investments that your medical affairs team should help you prepare for and debrief with you afterward.
For KOL engagement below the tier-one level, your Chief Medical Officer or VP of Medical Affairs owns the relationship. You receive a summary briefing on the KOL landscape twice per year, not a running update.
Publication Oversight: What CEOs Need to Know and What They Do Not
Publication strategy for pivotal data is legitimately a CEO concern. The decisions about how, when, and in what venue major clinical trial results are communicated reflect directly on the company’s scientific credibility and can have material commercial implications. These are not decisions to fully delegate.
However, CEOs who insert themselves into the granular details of publication planning, timeline management, author selection for secondary manuscripts, and congress abstract submissions are spending executive time at a level that belongs to the Chief Medical Officer and the publication committee.
A workable structure has two elements. First, a quarterly medical affairs leadership review where the CMO presents publication pipeline status: major publications expected in the next six months, current positioning of pivotal manuscripts, any publication delays with significant strategic implications, and the company’s performance on publication metrics such as time to disclosure and compliance with ICMJE standards. This is a 60-minute session focused on strategic implications, not operational status.
Second, a decision protocol for situations where CEO input is actually required: when a major publication is being positioned in a journal that will significantly affect how the data is received; when a publication timeline decision has significant commercial implications; or when there is a disagreement between medical affairs and commercial about how data should be framed. Outside of those situations, publication decisions stay within the function.
Efficient executive scheduling practices applied to medical affairs reviews keep these sessions focused on decisions rather than status updates.
Balancing Medical Science Time with Commercial Priorities
The relationship between medical affairs and commercial in pharmaceutical companies is structurally productive and regularly contentious. Medical affairs operates on scientific timelines, follows regulatory requirements about proactive scientific exchange, and is accountable to accuracy and completeness. Commercial operates on market timelines, is focused on revenue-generating activity, and is accountable to quarterly and annual performance targets.
The CEO sits at the apex of that tension. When medical affairs and commercial disagree about data communication strategy, launch support timing, or MSL-sales interaction boundaries, it often lands on your desk. Managing those escalations efficiently is a time management priority in itself.
The structural solution is a Medical Affairs and Commercial Leadership Forum: a standing monthly meeting, co-chaired by your CMO and Chief Commercial Officer, where cross-functional conflicts are surfaced and resolved at the leadership level before they require CEO intervention. The CEO receives a monthly summary of issues discussed and decisions made, attends quarterly (not monthly), and is escalated to only when the CMO and CCO cannot resolve a disagreement.
This forum does three things simultaneously: it keeps medical-commercial tensions from festering, it develops your leadership team’s capacity to resolve cross-functional issues, and it protects your time from being consumed by conflicts that have legitimate resolution mechanisms below the CEO level.
Building a Medical Affairs Time Budget
A practical time budget for a pharma CEO’s medical affairs engagement might look like the following. On a monthly basis: a 60-minute one-on-one with the CMO focused on strategic priorities rather than operational updates; attendance at the Medical Affairs and Commercial Leadership Forum once per quarter; and a brief (15-minute) review of the medical affairs dashboard, which your CMO should maintain and share on a standing basis.
On a quarterly basis: a 90-minute medical affairs leadership review covering publication pipeline, KOL landscape, MSL field performance, and budget status; and one or two external scientific engagements, such as an advisory board or a congress where your tier-one KOL relationships are being maintained.
On an annual basis: participation in medical affairs strategic planning; review and approval of the KOL engagement strategy for the year; and one major external scientific forum appearance where the CEO is represented as a scientific leader, not just a commercial executive.
Total annual time investment: roughly 60 to 80 hours, or 1.5 to 2 percent of a working year. That is meaningful engagement with a strategically critical function without sacrificing the time that belongs to enterprise leadership.
Managing Scientific Advisory Boards as a CEO Time Investment
Scientific advisory boards (SABs) are one of the highest-return external engagements a pharma CEO participates in. They concentrate your most important scientific relationships into structured formats, generate strategic input on your pipeline, and create the CEO-level scientific relationships that shape the company’s reputation in the medical community.
They are also significant time investments. A well-run SAB meeting requires two to three hours of CEO preparation, the meeting itself (typically a full day or day-and-a-half), and follow-up on the recommendations generated. If you have SABs for three therapeutic areas plus a company-wide pipeline advisory board, that is a substantial annual commitment.
The discipline is in governing SAB participation actively. Attend the full meeting only for the SABs tied to your most strategically critical programs. For other SABs, attend the opening session, deliver the strategic context-setting remarks, and participate in the closing discussion. Your CMO represents the company in the working sessions. This approach preserves the relationship value of CEO presence while recovering the operational time that would otherwise be spent in scientific deep-dives that belong to your medical leadership.
A structured executive support system ensures SAB logistics, briefing materials, and follow-up tracking do not consume CEO time that belongs to preparation and engagement.
When Medical Affairs Issues Escalate to the CEO
Despite good structural design, medical affairs issues will occasionally escalate to the CEO level. A regulatory agency inquiry about promotional materials that touch on medical affairs content. A significant data integrity concern about a publication. A senior KOL relationship that has deteriorated due to a perceived breach of scientific independence. A disagreement with a major academic medical center about collaborative research terms.
These situations require prompt CEO engagement precisely because they involve reputational, regulatory, or strategic risk that cannot be resolved at the function level. The time management discipline is twofold: ensuring your escalation protocols are clear so that genuine crises reach you quickly, and ensuring the protocol is not so permissive that routine issues are escalated to avoid accountability below the CEO level.
A well-designed escalation protocol specifies the categories of medical affairs issues that require CEO notification (regulatory inquiry, publication retraction, material KOL relationship damage, significant compliance finding) and the expected response timeline for each. Issues outside those categories are resolved by the CMO, with a summary to the CEO in the next standing one-on-one.
Conclusion
Time management for pharma medical affairs comes down to treating the function as what it is: a strategic asset with significant leverage over the company’s scientific positioning, clinical relationships, and regulatory standing, that requires CEO-level engagement at specific, well-defined points rather than continuous oversight.
Structure your KOL engagement around the relationships where CEO presence genuinely differentiates. Govern publication strategy at the strategic level and delegate the operational details. Build a structural bridge between medical affairs and commercial that resolves most cross-functional tensions without requiring CEO arbitration. Budget your annual medical affairs time investment explicitly and protect it from expansion.
The pharmaceutical companies that win in competitive therapeutic areas do so in part because their medical affairs functions operate with scientific credibility and commercial alignment simultaneously. That balance is a CEO responsibility. Managing your time around it is how you fulfill that responsibility without sacrificing the enterprise-level work that only you can do.